logo

Analyst Comments: ProLogis, Banco Bradesco, Sciele Pharma, Motorola, Eastman Chemical, Equifax, Astec Industries, Intersil
By: Zacks Investment Research   Thursday, September 04, 2008 8:38 AM

Vote for next session
The next market session will close:

ProLogis Still in Best Position

Operationally, ProLogis' (PLD) portfolio continues to perform well with stable occupancies and increasing rents. FFO (funds from operations) was $1.06 per share in 2Q08 versus $1.16 in 2Q07. The company reiterated its earlier full year 2008 FFO guidance range of $4.65 - $4.85 per share, with heavy CDFS (Corporate Distribution Facilities Services) income expected in the 4th quarter.

The US economy continues to slow; PLD has 65% of its asset base in the US, which adds to near term risk. The company is continuing to focus its development efforts outside of North America. We think PLD is still the best-positioned industrial REIT (real estate investment trust) with a stable balance sheet and global platform. Shares are off nearly 30% over the past three months. We maintain our Buy rating, and investors now have the opportunity to buy heavily discounted shares.

PLD now trades at 9.0x 2008 FFO estimates, putting it at a 5% discount to industrial and 40% discount to office REITs. The company has a large, diversified development pipeline, with high projected yields that should be accretive to earnings as projects come on line. With the decrease in share price, the yield is now over 4%, and the company is covering the payout with operating cash. Shares are attractively valued; we are setting our six month price target at 10.0x 2008 estimates or $50.00 per share.

Banco Bradesco Target Adjusted

We are continuing our Hold on Banco Bradesco S.A. (or Bradesco) (BBD), but cutting our target price to $19. In its second quarter report, Bradesco posted net earnings before nonrecurring items of R$2,002 million, up 11% year-over-year, but below our estimate due to a higher-than-expected effective tax rate.

Despite this, we are maintaining our 2008 EPADS estimate at $1.60 and raising our 2009 estimate to $1.90 from $1.88, due to a change in our FX assumptions from depreciation of the US$ against the Brazilian real. Revenues should benefit from growth in the lending portfolio, though net interest margins are declining and loss provisions should rise. We believe the $0.61 indicated dividend, which provides a 3.3% yield, is safe.

As a result of better economic conditions, the Brazilian credit business has been growing, and Bradesco has been able to take advantage of this improved economic environment. Due to Bradesco's successful segmentation strategy, it has experienced solid portfolio growth in consumer and small- and medium-size companies. During second quarter 2008, Bradesco's loan portfolio increased 37% over 2007's second quarter, reaching R$148 billion. We expect continued strong growth in upcoming quarters.

The bank continues to show strong profitability due to strict cost controls, growth in assets, solid fee income growth, increased credit portfolio, and remarkable growth in its assets under management. As expected, Brazilian retail banks benefited from the uncommon combination of increasing credit demand and higher local interest rates.

Sciele Target the Buyout Price

On September 1, Sciele Pharma, Inc. (SCRX) entered into a definitive agreement with Japanese company Shionogi for $1.4 billion, or $31 per share. The offer price represents a huge 61% premium over Sciele's closing price on August 29. Sciele s shares shot up 59% following the takeover announcement. We previously had a Buy rating on Sciele but are now moving back to a Hold rating.

We believe that Sciele has done a good job saving the Sular franchise from generic erosion. In our opinion, Sciele's strong sales and marketing experience and solid late-stage pipeline should help Shionogi strengthen its presence in the U.S. market once the acquisition goes through in the fourth quarter of 2008.

Our new target price on Sciele is $31, which is based on Shionogi's offer price.


Next Page >>123

(2)
 
2/24/2009 9:28:45 PM
by Richard Woon
Great call by Zacks huh? PLD now trades at $6 and change.
Rating: (0) (0)
3/31/2009 2:11:17 AM
Ryan-Stock Market Prices for Motorola by Ryan
Motorola was hit by the bad market position.Some analysts think that it sold only 40 million handsets in the fourth quarter. Rival Nokia Corp usually moves about 100 million. The Razr's success is now just a memory.Most shareholders wish that the stock would hit the lower number.There has been much talk about breaking the company into pieces.Motorola is launching it's new cell phone in the market in the mid of 2009 and then they wiil be ready to compete with Nokia and Samsung.Their all time highest share price of $60 goes down to $4.20 on 30th March.Go to "http://www.stocknod.com/MOT-Motorola-stock-prices.aspx to check the share price of Motorola.
Rating: (0) (0)
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

The above story is the opinion of the author only and it does not reflect iStockAnalyst opinion. Further, the author is not personally advising you regarding the suitability of the story for your investment needs. In no event iStockAnalyst will be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from or arising out of, or in connection with the use of this information. Please consult your investment advisor before making any investment decision.
  
Advertisement
Popular Articles
Related Press Releases
Advertisement
Partner Center
Recent Articles by Zacks Investment Research



Subscribe to Email Alerts rss feed or RSS feeds rss feed for articles from more than 500 contributors, press releases, SEC filings and full text news from more than four thousand sources.
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia